Moniyot-131 Zur Therapie (Sodium Iodide (131i))

Sodium Iodide (I-131) is actively taken up by thyroid cells via the sodium‑iodide symporter. Inside the gland, the isotope emits beta radiation that damages cellular DNA, leading to selective destruction of thyroid tissue, while gamma emissions enable imaging and dose verification.

The appropriate dose of Moniyot-131 Zur Therapie is determined by the prescribing physician based on the patient’s clinical condition, thyroid uptake studies, and treatment goals. Dosage is individualized and not standardized across all patients.

The safety of Moniyot-131 Zur Therapie in pregnancy and breastfeeding is not established. It is generally avoided because radioactive iodine can cross the placenta and enter breast milk, potentially harming the fetus or infant. Consultation with a specialist is essential before use.

To order Moniyot-131 Zur Therapie, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moniyot-131 Zur Therapie is a radioactive iodine option that offers targeted tissue ablation with a single oral dose, unlike antithyroid drugs that require prolonged oral therapy. Compared with external beam radiation, I-131 provides selective thyroid uptake, reducing exposure to surrounding tissues.

Moniyot-131 Zur Therapie should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Follow local regulations for handling radioactive materials, including using appropriate shielding and disposal procedures.

The medication is administered orally as a single dose, usually in capsule or liquid form, under the supervision of a qualified nuclear medicine specialist. Patients may be instructed to drink plenty of fluids and follow radiation safety guidelines after ingestion.

Serious risks include severe sialadenitis, bone marrow suppression leading to pancytopenia, pulmonary fibrosis, allergic reactions, and the rare possibility of secondary malignancies due to radiation exposure. Patients should be monitored closely for these complications.

Moniyot-131 Zur Therapie is contraindicated in pregnant or breastfeeding women, patients with severe renal impairment, those with known hypersensitivity to iodine or radioactive iodine, and individuals unable to comply with radiation safety precautions.